Vaccine Design and Testing – News and Features

News
Personalized Probiotic Bacteria Vaccine Shows Promise as Cancer Immunotherapy
Researchers have created engineered probiotic bacteria that educate the immune system to attack cancer cells, showing promising results in mouse models. These personalized bacterial vaccines could lead to effective treatments for advanced cancers.

News
Potentially Longer-Lasting Covid Vaccine Targets Identified
Researchers identified more than 200 new vaccine target candidates from SARS-CoV-2, focusing on seven viral proteins beyond the Spike protein. These candidates could enhance immunity by triggering T cell responses.

News
Enzyme Engineered To Produce Threose Nucleic Acid, a Synthetic Genetic Material
Researchers have engineered an enzyme to produce synthetic genetic material, advancing the discovery of new therapeutics for cancer and autoimmune, metabolic and infectious diseases.

Industry Insight
Getting New Drug Modalities to Market: How Can Your Data Strategy Help?
This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI efforts.

News
Previous COVID-19 Infections Protect Against Severe Cases of the Flu
Recovery from COVID-19 infection can have a protective effect against the worst effects of flu, and this memory response comes from an unexpected corner of the immune system.

News
Natural Immunity Enhances Response to Influenza Vaccines
A study reveals that natural immunity gained from previous influenza infections enhances immune responses to subsequent vaccinations. This finding suggests that individuals who contract the flu may benefit in their battle against future strains.

Article
Understanding Bioprocessing, Its Applications and the Role of a Bioreactor
Bioprocessing involves the production of a high-value-added product from a living source. In this article, the stages of bioprocessing are described, with a focus on the central piece of this concept: the bioreactor.

News
Promising Lassa Fever Vaccine Prevents Disease and Death in Preclinical Animal Models
Researchers developed the LASSARAB vaccine, using a deactivated rabies virus to protect against Lassa fever. In preclinical trials, it prevented severe disease and death in animals.

News
Solving the Mystery of Hepatitis C
Around 300,000 people die from hepatitis C every year. A new study is the first to map the protein complex that enables the virus to infect our cells, potentially paving the way for an effective vaccine.

News
Monoclonal Antibody Shows Promise Against Multiple COVID-19 Variants
The monoclonal antibody SC27 effectively neutralizes numerous SARS-CoV-2 variants and related coronaviruses. SC27 targets multiple sites on the spike protein, showing broad protection in lab tests and animal models.
Advertisement